X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (131) 131
index medicus (104) 104
hematology (83) 83
male (70) 70
oncology (70) 70
female (69) 69
aged (67) 67
middle aged (57) 57
adult (41) 41
aged, 80 and over (38) 38
leukemia, myeloid, acute - drug therapy (38) 38
treatment outcome (32) 32
cancer (30) 30
hematology, oncology and palliative medicine (30) 30
acute myeloid-leukemia (29) 29
myelodysplastic syndromes (29) 29
prognosis (28) 28
chemotherapy (24) 24
leukemia (24) 24
acute myeloid leukemia (23) 23
antineoplastic agents - therapeutic use (23) 23
survival (23) 23
leukemia, myeloid, acute - mortality (22) 22
article (21) 21
acute myelogenous leukemia (20) 20
myelodysplastic syndromes - drug therapy (20) 20
abridged index medicus (19) 19
medicine, general & internal (18) 18
mutation (18) 18
retrospective studies (18) 18
risk (18) 18
therapy (17) 17
antineoplastic combined chemotherapy protocols - therapeutic use (16) 16
myelodysplastic syndromes - mortality (16) 16
remission induction (16) 16
young adult (16) 16
analysis (15) 15
care and treatment (15) 15
clinical trials as topic (14) 14
cytarabine (14) 14
leukemia, myeloid, acute - diagnosis (14) 14
mds (14) 14
myelodysplastic syndromes - pathology (14) 14
survival analysis (14) 14
aml (13) 13
risk factors (13) 13
cytogenetics (12) 12
leukemia, myeloid, acute - pathology (12) 12
survival rate (12) 12
myelodysplastic syndromes - diagnosis (11) 11
research (11) 11
antineoplastic combined chemotherapy protocols - adverse effects (10) 10
expression (10) 10
leukemia, myeloid, acute - genetics (10) 10
myelodysplastic syndrome (10) 10
older patients (10) 10
age (9) 9
antineoplastic agents - adverse effects (9) 9
azacitidine (9) 9
classification (9) 9
cytarabine - administration & dosage (9) 9
disease progression (9) 9
disease-free survival (9) 9
mutations (9) 9
myelodysplastic syndromes - genetics (9) 9
salvage therapy (9) 9
scoring system (9) 9
trial (9) 9
acute disease (8) 8
adolescent (8) 8
antimetabolites, antineoplastic - therapeutic use (8) 8
antineoplastic agents - administration & dosage (8) 8
elderly-patients (8) 8
farnesyltranstransferase - antagonists & inhibitors (8) 8
internal medicine (8) 8
leukemia, myeloid, acute - therapy (8) 8
medical research (8) 8
oncology, experimental (8) 8
signal transduction (8) 8
thalidomide - analogs & derivatives (8) 8
bone marrow (7) 7
bone marrow - pathology (7) 7
cells (7) 7
daunorubicin (7) 7
enzyme inhibitors - therapeutic use (7) 7
follow-up studies (7) 7
hematologic neoplasms - drug therapy (7) 7
kaplan-meier estimate (7) 7
lenalidomide (7) 7
leukemia, myeloid - drug therapy (7) 7
medicine & public health (7) 7
myelodysplastic syndromes - therapy (7) 7
quinolones - therapeutic use (7) 7
southwest-oncology-group (7) 7
transplantation (7) 7
treatment failure (7) 7
adults (6) 6
alkyl and aryl transferases - antagonists & inhibitors (6) 6
antineoplastic agents - pharmacology (6) 6
antineoplastic combined chemotherapy protocols - administration & dosage (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 1, pp. 112 - 121
Summary Background Clonal haemopoiesis of indeterminate potential (CHIP) is an age-associated genetic event linked to increased risk of primary haematological... 
Hematology, Oncology and Palliative Medicine | ADJUVANT CHEMOTHERAPY | BREAST-CANCER | COLON-CANCER | VARIANTS | ONCOLOGY | FORMAT | SEQUENCE | MUTATIONS | LEUKEMIA | OUTCOMES | MYELODYSPLASTIC SYNDROMES | Clone Cells - drug effects | Prognosis | Follow-Up Studies | Humans | Leukemia, Myeloid, Acute - epidemiology | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Case-Control Studies | Incidence | Neoplasms, Second Primary - chemically induced | Myelodysplastic Syndromes - chemically induced | Aged, 80 and over | Female | Neoplasms, Second Primary - genetics | High-Throughput Nucleotide Sequencing - methods | Leukemia, Myeloid, Acute - chemically induced | Florida - epidemiology | Risk Factors | Hematopoiesis - genetics | Survival Rate | Mutation - genetics | Myelodysplastic Syndromes - epidemiology | Clone Cells - metabolism | Neoplasms - drug therapy | Neoplasms, Second Primary - diagnosis | Neoplasms, Second Primary - epidemiology | Myelodysplastic Syndromes - diagnosis | Clone Cells - pathology | Leukemia, Myeloid, Acute - diagnosis | Aged | Biomarkers, Tumor - genetics | Myelodysplastic Syndromes - genetics | Neoplasm Staging | Neoplasms - pathology | Leukemia, Myeloid, Acute - genetics | Care and treatment | Chemotherapy | Oncology, Experimental | Mortality | Aged patients | Research | Epidemiology | Cancer | Development and progression
Journal Article
The Lancet, ISSN 0140-6736, 2005, Volume 365, Issue 9468, pp. 1362 - 1362
The Nobel economics committee is currently researching this year's nominees, one of whom should certainly be [Jeffrey Sachs]. By happy coincidence, Sachs is... 
MEDICINE, GENERAL & INTERNAL | Nobel Prize | Economics - history | Famous Persons | History, 20th Century | Humans | Economics | Achievements and awards | Health care | Winners | Global economy | Nobel prizes | Economic development
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 9, pp. 1025 - 1036
Journal Article
Clinical Lymphoma, Myeloma and Leukemia, ISSN 2152-2650, 09/2019, Volume 19, pp. S89 - S91
Journal Article
Blood, ISSN 0006-4971, 05/2014, Volume 123, Issue 21, pp. 3239 - 3246
Journal Article
Scientific reports, ISSN 2045-2322, 12/2019, Volume 9, Issue 1, pp. 606 - 12
Journal Article
Best Practice & Research Clinical Haematology, ISSN 1521-6926, 12/2018, Volume 31, Issue 4, pp. 387 - 390
Older adults with acute myeloid leukemia (AML) traditionally have very poor survival outcomes. Those who receive only supportive care have worse overall... 
AML | Hypomethylating | Intensive | Glasdegib | Acute myeloid leukemia | Elderly | Survival | Venetoclax | CPX-351 | ACUTE MYELOID-LEUKEMIA | PHASE-3 | REGIMENS | CARE | TRIAL | TIPIFARNIB | LOW-DOSE CYTARABINE | INHIBITOR | HEMATOLOGY | Aged | Analysis | Leukemia | Patient outcomes
Journal Article
Future Oncology, ISSN 1479-6694, 05/2018, Volume 14, Issue 12, pp. 1147 - 1154
Multiple novel therapeutic agents against acute myeloid leukemia (AML) have been evaluated in the past several decades without meaningful clinical improvement... 
older adults with AML | secondary AML | therapy-related AML | acute myeloid leukemia | induction chemotherapy | CPX-351 | AML | LIPOSOME INJECTION | ADULTS | MOLAR RATIO | CYTARABINE | DAUNORUBICIN | OLDER PATIENTS | PHARMACOKINETICS | ONCOLOGY | CYTARABINEDAUNORUBICIN | CYTARABINE/DAUNORUBICIN
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2018, Volume 36, Issue 26, pp. 2684 - 2692
PurposeCPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin that delivers a synergistic 5:1 drug ratio into leukemia cells to a... 
AML | ADULT PATIENTS | THERAPY | ONCOLOGY | CYTARABINEDAUNORUBICIN | MOLAR RATIO | FORMULATION | CYTOTOXICITY | CHEMOTHERAPY | CLINICAL-SIGNIFICANCE | AGE | RAPID COMMUNICATION
Journal Article
by Lander, Eric S and Linton, Lauren M and Birren, Bruce and Nusbaum, Chad and Zody, Michael C and Baldwin, Jennifer and Devon, Keri and Dewar, Ken and Doyle, Michael and Fitzhugh, William and Funke, Roel and Gage, Diane and Harris, Katrina and Heaford, Andrew and Howland, John and Kann, Lisa and Lehoczky, Jessica and Levine, Rosie and McEwan, Paul and McKernan, Kevin and Meldrim, James and Mesirov, Jill P and Miranda, Cher and Morris, William and Naylor, Jerome and Raymond, Christina and Rosetti, Mark and Santos, Ralph and Sheridan, Andrew and Sougnez, Carrie and Stange-Thomann, Nicole and Stojanovic, Nikola and Subramanian, Aravind and Wyman, Dudley and Rogers, Jane and Sulston, John and Ainscough, Rachael and Beck, Stephan and Bentley, David and Burton, John and Clee, Christopher and Carter, Nigel and Coulson, Alan and Deadman, Rebecca and Deloukas, Panos and Dunham, Andrew and Dunham, Ian and Durbin, Richard and French, Lisa and Grafham, Darren and Gregory, Simon and Hubbard, Tim and Humphray, Sean and Hunt, Adrienne and Jones, Matthew and Lloyd, Christine and McMurray, Amanda and Matthews, Lucy and Mercer, Simon and Milne, Sarah and Mullikin, James C and Mungall, Andrew and Plumb, Robert and Ross, Mark and Shownkeen, Ratna and Sims, Sarah and Waterston, Robert H and Wilson, Richard K and Hillier, Ladeana W and McPherson, John D and Marra, Marco A and Mardis, Elaine R and Fulton, Lucinda A and Chinwalla, Asif T and Pepin, Kymberlie H and Gish, Warren R and Chissoe, Stephanie L and Wendl, Michael C and Delehaunty, Kim D and Miner, Tracie L and Delehaunty, Andrew and Kramer, Jason B and Cook, Lisa L and Fulton, Robert S and Johnson, Douglas L and Minx, Patrick J and Clifton, Sandra W and Hawkins, Trevor and Branscomb, Elbert and Predki, Paul and Richardson, Paul and Wenning, Sarah and Slezak, Tom and Doggett, Norman and Cheng, Jan-Fang and Olsen, Anne and Lucas, Susan and Elkin, Christopher and Uberbacher, Edward and Frazier, Marvin and ... and Int Human Genome Sequencing Conso and International Human Genome Sequencing Consortium
Nature, ISSN 0028-0836, 02/2001, Volume 409, Issue 6822, pp. 860 - 921
Journal Article